News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
869,257 Results
Type
Article (87906)
Company Profile (825)
Press Release (780511)
Multimedia
Podcasts (191)
Webinars (28)
Section
Business (233240)
Career Advice (4145)
Deals (39867)
Drug Delivery (146)
Drug Development (91401)
Employer Resources (204)
FDA (18379)
Job Trends (17422)
News (397856)
Policy (39961)
Tag
Academia (3006)
Academic (2)
Accelerated approval (33)
Adcomms (36)
Allergies (142)
Alliances (56981)
ALS (180)
Alzheimer's disease (1784)
Antibody-drug conjugate (ADC) (335)
Approvals (18547)
Artificial intelligence (614)
Autoimmune disease (154)
Automation (34)
Bankruptcy (406)
Best Places to Work (12634)
BIOSECURE Act (23)
Biosimilars (198)
Biotechnology (489)
Bladder cancer (160)
Brain cancer (64)
Breast cancer (645)
Cancer (4926)
Cardiovascular disease (433)
Career advice (3567)
Career pathing (40)
CAR-T (300)
CDC (59)
Celiac Disease (1)
Cell therapy (815)
Cervical cancer (37)
Clinical research (76895)
Collaboration (1750)
Company closure (5)
Compensation (1122)
Complete response letters (70)
COVID-19 (2988)
CRISPR (96)
C-suite (827)
Cystic fibrosis (154)
Data (6150)
Decentralized trials (2)
Denatured (70)
Depression (146)
Diabetes (526)
Diagnostics (7207)
Digital health (44)
Diversity (13)
Diversity, equity & inclusion (49)
Drug discovery (294)
Drug pricing (220)
Drug shortages (36)
Duchenne muscular dystrophy (233)
Earnings (100037)
Editorial (61)
Employer branding (25)
Employer resources (173)
Events (134968)
Executive appointments (1025)
FDA (21453)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (24)
Funding (1532)
Gene editing (210)
Generative AI (62)
Gene therapy (661)
GLP-1 (1110)
Government (5432)
Grass and pollen (8)
Guidances (382)
Healthcare (20941)
HIV (60)
Huntington's disease (48)
IgA nephropathy (86)
Immunology and inflammation (287)
Immuno-oncology (54)
Indications (84)
Infectious disease (3272)
Inflammatory bowel disease (202)
Inflation Reduction Act (17)
Influenza (118)
Intellectual property (239)
Interviews (816)
IPO (17952)
IRA (60)
Job creations (5198)
Job search strategy (2866)
Kidney cancer (17)
Labor market (90)
Layoffs (657)
Leadership (39)
Legal (10158)
Liver cancer (97)
Longevity (14)
Lung cancer (673)
Lymphoma (369)
Machine learning (43)
Management (66)
Manufacturing (821)
MASH (171)
Medical device (15001)
Medtech (15045)
Mergers & acquisitions (22954)
Metabolic disorders (1367)
Multiple sclerosis (157)
NASH (23)
Neurodegenerative disease (343)
Neuropsychiatric disorders (93)
Neuroscience (3068)
NextGen: Class of 2026 (7707)
Non-profit (5110)
Now hiring (63)
Obesity (657)
Opinion (331)
Ovarian cancer (162)
Pain (198)
Pancreatic cancer (226)
Parkinson's disease (288)
Partnered (39)
Patents (490)
Patient recruitment (458)
Peanut (60)
People (66818)
Pharmaceutical (145)
Pharmacy benefit managers (31)
Phase I (23765)
Phase II (33362)
Phase III (25151)
Pipeline (4685)
Policy (329)
Postmarket research (3554)
Preclinical (10682)
Press Release (72)
Prostate cancer (239)
Psychedelics (53)
Radiopharmaceuticals (298)
Rare diseases (868)
Real estate (7437)
Recruiting (80)
Regulatory (28865)
Reports (66)
Research institute (2721)
Resumes & cover letters (651)
Rett syndrome (27)
RNA editing (20)
RSV (83)
Schizophrenia (157)
Series A (254)
Series B (193)
Service/supplier (30)
Sickle cell disease (103)
Special edition (27)
Spinal muscular atrophy (175)
Sponsored (48)
Startups (4333)
State (2)
Stomach cancer (20)
Supply chain (112)
Tariffs (98)
The Weekly (119)
Vaccines (1129)
Venture capital (92)
Weight loss (455)
Women's health (85)
Worklife (21)
Date
Today (5)
Last 7 days (556)
Last 30 days (1909)
Last 365 days (33076)
2026 (1570)
2025 (33226)
2024 (38142)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51337)
2018 (39122)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1290)
Alabama (87)
Alaska (7)
Arizona (339)
Arkansas (14)
Asia (51494)
Australia (9034)
California (11329)
Canada (3265)
China (1134)
Colorado (477)
Connecticut (492)
Delaware (342)
Europe (118299)
Florida (1655)
Georgia (363)
Hawaii (3)
Idaho (68)
Illinois (942)
India (66)
Indiana (534)
Iowa (23)
Japan (412)
Kansas (132)
Kentucky (42)
Louisiana (29)
Maine (83)
Maryland (1440)
Massachusetts (8382)
Michigan (349)
Minnesota (649)
Mississippi (6)
Missouri (137)
Montana (35)
Nebraska (28)
Nevada (123)
New Hampshire (85)
New Jersey (3063)
New Mexico (33)
New York (3005)
North Carolina (1585)
North Dakota (10)
Northern California (5400)
Ohio (348)
Oklahoma (22)
Oregon (54)
Pennsylvania (2271)
Puerto Rico (21)
Rhode Island (49)
South America (1657)
South Carolina (62)
South Dakota (1)
Southern California (4364)
Tennessee (173)
Texas (1787)
United States (40989)
Utah (340)
Vermont (1)
Virginia (283)
Washington D.C. (85)
Washington State (953)
West Virginia (4)
Wisconsin (122)
Wyoming (2)
There are 869,257 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
IN PARTNERSHIP WITH LOTTE BIOLOGICS
LOTTE Biologics Tightens Global Quality as Syracuse ADC Hub Ramps for 2026
With inspections always on the table, LOTTE Biologics is pushing a proactive, quality first culture across its dual hubs in Syracuse and Songdo, backing its new single‑use ADC facility with rigorous training, self‑audits and real‑time regulatory surveillance.
January 19, 2026
·
2 min read
·
Jennifer Smith-Parker
Job Trends
Report: U.S. Life Sciences Job Market Report Q4 2025
BioSpace’s 2025 Q4 U.S. Life Sciences Job Market update highlights early signs of stabilization in biopharma hiring, with modest gains in job postings, slowing layoffs, and cautiously improving sentiment heading into 2026.
January 19, 2026
·
1 min read
·
BioSpace Insights
Alzheimer’s disease
4 Next-Gen Candidates That Could Form the Future of Alzheimer’s Treatment
Following the hard-won success of early anti-amyloid drugs, a new generation of Alzheimer’s modalities—from tau-targeting gene silencers to blood-brain barrier delivery platforms—is entering the pipeline to anchor future combination therapies.
January 19, 2026
·
7 min read
·
Ben Hargreaves
FDA
JPM26: Beam, Cabaletta, More Zero In on Regulatory Alignment After Tumultuous Year
As biotechs faced investors at the J.P. Morgan Healthcare Conference this week, they emphasized agreement with the FDA on clinical trial design and regulatory pathways to approval. Atara, meanwhile, lamented the agency’s “complete reversal of position” after its therapy for a rare surgical complication was rejected.
January 19, 2026
·
6 min read
·
Heather McKenzie
Sponsored
After the JPM Hype, a Reality Check: Why your 2026 Strategy Hinges on your Manufacturing Toolkit
After J.P. Morgan, biotech’s bold promises meet real-world challenges. In 2026, success starts with a CDMO partner who accelerates timelines and anticipates every manufacturing hurdle. Learn how AGC Biologics offers tailored cell line solutions for complex molecules.
January 19, 2026
·
3 min read
Press Releases
Hemostemix Receives FDA Support for Its Basket Protocol Approach
January 16, 2026
·
8 min read
Layoffs
Vedanta ‘Significantly’ Reduces Staff, Focuses on Phase III Study of
C. Diff
Drug
Less than six months after cutting 20% of its employees, Vedanta Biosciences has again laid off staff. According to one affected staffer, half of
the Cambridge, Massachusetts–based biotech’s workforce is being cut while most of the rest are furloughed.
January 16, 2026
·
2 min read
·
Angela Gabriel
Business
JPM26: Protagonist Has a $400M Decision To Make. It’s a No-Brainer
Following rusfertide’s triumphant Phase III trial last year, Protagonist must decide how involved to be in future development. Hundreds of millions of dollars are on the line.
January 16, 2026
·
2 min read
·
Annalee Armstrong
Press Releases
Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
January 16, 2026
·
8 min read
Press Releases
Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
January 16, 2026
·
8 min read
1 of 86,926
Next
